NCT00395460 - Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Central Nervous System Diseases

Interventions

DRUG

Gadobutrol (Gadavist, Gadovist, BAY86-4875)

1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)

DRUG

Magnevist

0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)

Trial Locations (4)

Chinese PLA General Hosp., Beijing

Fudan University Huashan Hospital, Shanghai

Jiangsu Province Hospital, Nanjing

The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an